Dr Kazarian points out that retatrutide hasn't been approved yet, so he says anyone using it now isn't getting the genuine drug from Lilly.
Recap by typeshit. Post by @drkazarian on Instagram.
European regulators first raised NAION, a rare optic nerve condition sometimes called an eye stroke, as a possible risk more than 15 months ago.
Obesity doctor Spencer Nadolsky takes on six popular misconceptions about Ozempic in a quick social video. The caption doesn't say which myths are covered.
Users described more appetite, fatigue, extra energy and insomnia. An analysis of Reddit comments, not a clinical trial, so the findings come from self-reports.
Online sellers pitch peptides for weight loss, anti-aging and muscle gain, and Gavin Coote's full story looks at the risks of products nobody regulates.
Eligible beneficiaries can get some GLP-1 drugs cheaper, but BMI and medical conditions decide who qualifies, and it runs apart from Part D.
Orexo says its first preclinical in vivo study of an oral semaglutide built on AmorphOX showed promising bioavailability. Animal data only so far.
Loading…